loading

INVITRO INTERNATIONAL’S 1st HALF FY 2001 PRODUCES NET PROFIT VS. PRIOR YEAR LOSS

Website Data Base Sales To Start Soon
Invitro International
Contact: W. Richard Ulmer
17751 Sky Park East, Suite G
(800) 2-INVITRO
Irvine, CA 92614
http://www.invitrointl.com
Irvine, CA May 1, 2001- InVitro International (OTC, IVRO) reported today that first six months sales results were $297,858, 11% under the same period in FY 2000. However, net profit for first half 2001 of $9,370 compared favorably to a net loss of $$95,249 a year ago. IVRO CEO & President, W. Richard Ulmer said:”We bounced back from a financially disappointing first fiscal quarter with second quarter sales results as strong as any since 1996. That allowed us to post a small net profit with increased prospects for a strong second half. Our cash remains strong; we’re debt free; we’ve increased our advertising spend; and we just completed a program in China where we were invited to speak to nearly 50 prospect companies and a university, all of whom were interested in minimizing animal testing there.”

In other company news, InVitro announced previously that Transport Canada has fully accepted Corrositex as a replacement for animal testing. This recent approval (Jan ’01) combines well with the company’s plans to expand its e-commerce capabilities by offering a significant portion of the Corrositex data base on its website. Each should help increase Corrositex global sales volume in the coming months.

This press release may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: acceptance of the Company’s technology by customers or regulatory agencies, changes in market conditions and other competitive factors. Any such forward-looking statements are not guarantees of future performance.
Irvine, CA May 1, 2001- InVitro International (OTC, IVRO) reported today that first six months sales results were $297,858, 11% under the same period in FY 2000. However, net profit for first half 2001 of $9,370 compared favorably to a net loss of $$95,249 a year ago. IVRO CEO & President, W. Richard Ulmer said:”We bounced back from a financially disappointing first fiscal quarter with second quarter sales results as strong as any since 1996. That allowed us to post a small net profit with increased prospects for a strong second half. Our cash remains strong; we’re debt free; we’ve increased our advertising spend; and we just completed a program in China where we were invited to speak to nearly 50 prospect companies and a university, all of whom were interested in minimizing animal testing there.”

In other company news, InVitro announced previously that Transport Canada has fully accepted Corrositex as a replacement for animal testing. This recent approval (Jan ’01) combines well with the company’s plans to expand its e-commerce capabilities by offering a significant portion of the Corrositex data base on its website. Each should help increase Corrositex global sales volume in the coming months.

This press release may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: acceptance of the Company’s technology by customers or regulatory agencies, changes in market conditions and other competitive factors. Any such forward-looking statements are not guarantees of future performance.

Posted on Categories News

Leave a Reply

Your email address will not be published. Required fields are marked *